CDE Includes Beijing Toll Biotech's TollB‑001 Tablets in Rare Disease Pilot Scheme – Novel Oral TLR8 Inhibitor Targets Systemic Sclerosis with First Specific Treatment Potential
CompanyDrug

CDE Includes Beijing Toll Biotech’s TollB‑001 Tablets in Rare Disease Pilot Scheme – Novel Oral TLR8 Inhibitor Targets Systemic Sclerosis with First Specific Treatment Potential

According to the latest public notice from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA), TollB‑001 Tablets from Beijing Toll Biotech Co., Ltd. have been…

CSPC Pharmaceutical Initiates Phase II Trial of SYH2069 – Novel Long‑Acting GLP‑1R/GIPR Dual Agonist with Dual‑Biased Activity for Adult Type 2 Diabetes
CompanyDrug

CSPC Pharmaceutical Initiates Phase II Trial of SYH2069 – Novel Long‑Acting GLP‑1R/GIPR Dual Agonist with Dual‑Biased Activity for Adult Type 2 Diabetes

GenScript Biotech Collaborates with Lilly TuneLab – Pairing Large‑Scale Wet‑Lab Validation with Eli Lilly's AI/ML Drug Discovery Platform
CompanyDeals

GenScript Biotech Collaborates with Lilly TuneLab – Pairing Large‑Scale Wet‑Lab Validation with Eli Lilly’s AI/ML Drug Discovery Platform

Novo Nordisk and Anthropic Announce AI Collaboration – Claude Science to Accelerate Drug Discovery and AI‑Driven Software Development
CompanyDeals

Novo Nordisk and Anthropic Announce AI Collaboration – Claude Science to Accelerate Drug Discovery and AI‑Driven Software Development

NMPA Grants Priority Review to Everest Medicines' Manufacturing‑Transfer NDA for VELSIPITY (Etrasimod) – Localizing Production of Its Approved Ulcerative Colitis Therapy in China
CompanyDrug

NMPA Grants Priority Review to Everest Medicines’ Manufacturing‑Transfer NDA for VELSIPITY (Etrasimod) – Localizing Production of Its Approved Ulcerative Colitis Therapy in China

- Advertisement -
Ad image
Eli Lilly's Foundayo (Orforglipron) Demonstrates Significant Weight Loss Across All Menopausal Stages – Addresses Critical Gap in Women's Metabolic Health
CompanyDrug

Eli Lilly’s Foundayo (Orforglipron) Demonstrates Significant Weight Loss Across All Menopausal Stages – Addresses Critical Gap in Women’s Metabolic Health

CompanyDrug

Antengene Unveils ATG-207 Bispecific Fusion Protein Data at EULAR 2026 – Novel αCD3×TGF-β Molecule Shows Potent Immunomodulatory Activity in Autoimmune Models

CompanyDrug

Sciwind Biosciences Unveils Superior Weight Loss Data for Ecnoglutide vs. Semaglutide at ADA 2026 – First cAMP-Biased GLP-1 Agonist Shows 35% Greater Efficacy

MSD Launches Winrevair (Sotatercept) in China – First Activin Signaling Inhibitor for Pulmonary Arterial Hypertension
CompanyDrug

MSD Launches Winrevair (Sotatercept) in China – First Activin Signaling Inhibitor for Pulmonary Arterial Hypertension

CompanyDeals

Junshi Biosciences Forms Strategic JV with Zhiyu Biomedicine, Contributing Oncology Antibody IP and ADC Platform for Multispecific Development

CompanyDeals

Everest Medicines Licenses LNZ100 Presbyopia Treatment from Corxel for Greater China – Aceclidine-Based Eye Drop Offers Novel Miotic Mechanism

Guangzhou Lupeng's Rocbrutinib Receives NMPA Priority Approval for Relapsed/Refractory Mantle Cell Lymphoma – Fourth-Generation BTK Inhibitor Shows 63.9% Response Rate
CompanyDrug

Guangzhou Lupeng’s Rocbrutinib Receives NMPA Priority Approval for Relapsed/Refractory Mantle Cell Lymphoma – Fourth-Generation BTK Inhibitor Shows 63.9% Response Rate

Policy / Regulatory

China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development

CompanyDrug

Sichuan Biokin Receives NMPA Go-Ahead for BL-M08D1 Bispecific Antibody in DLBCL Combination Therapy – ADC Leverages Proven BL-B01D1 Platform

CompanyDrug

Mabwell Bioscience Secures NMPA Clinical Approval for 9MW5211 in Inflammatory Bowel Disease – Highly Specific Depleting Antibody Targets Pathogenic Immune Cells

CompanyDeals

SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets

CompanyDrug

Shanghai Bao Pharmaceuticals’ KJ103 NDA Accepted by NMPA – First-in-Class IgG Degrading Enzyme for Highly Sensitized Kidney Transplant Patients

Show More